Showing 17,541 - 17,560 results of 21,342 for search '(( significant role decrease ) OR ( significant decrease decrease ))', query time: 0.73s Refine Results
  1. 17541

    Table 4_The impact of Helicobacter pylori infection and eradication therapies on gut microbiota: a systematic review of microbial dysbiosis and its implications in gastric carcinog... by Alia Albush (21669206)

    Published 2025
    “…H. pylori infection resulted in significant alterations in gut and gastric microbiota, with a notable increase in inflammation-associated bacteria, such as Proteobacteria and Streptococcus. …”
  2. 17542

    Image 2_The global, regional, and national alcohol-related colorectal cancer burden and forecasted trends: results from the global burden of disease study 2021.tif by Jinfeng Yao (2200615)

    Published 2024
    “…From 1990 to 2021, the number of cases increased, but the Age-Standardized Rate (ASR) decreased. The trends in disease burden predicted by the two models for 2022–2046 were not consistent.…”
  3. 17543

    Presentation 1_A framework for modeling county-level COVID-19 transmission.pdf by Yida Bao (15255682)

    Published 2025
    “…We then use Moran's I to evaluate spatial clustering, prompting Spatial Autoregressive and Spatial Error Models when autocorrelation is significant. Notably, spatial models outperform the Ordinary Least Squares approach—R<sup>2</sup> rises from 0.4849 with Ordinary Least Squares to 0.6846 under Spatial Error Model, while RMSE decreases from 2.0891 to 1.642—demonstrating improved fit and more accurate spatial transmission dynamics. …”
  4. 17544

    Table 5_Pachymic acid alleviates metabolic dysfunction-associated steatotic liver disease by inhibiting ferroptosis through PPARα.xls by Guilin Ren (18720749)

    Published 2025
    “…</p>Results<p>HFD induced biochemical abnormalities and liver injury, which were significantly reversed by Pac, as evidenced by decreased plasma levels of AST (Aspartate aminotransferase), ALT (Alanine aminotransferase), TG (Triglyceride), and TC (Total cholesterol), and reduced hepatic TG and TC levels. …”
  5. 17545

    Raw data of the subsystem. by Jie Huang (104235)

    Published 2025
    “…Spatially, the CCD demonstrates a characteristic pattern of decreasing from east to west. Overall, achieving a “cross-level transition” in CCD is challenging, and the neighboring provinces significantly influence the enhancement of local CCD. …”
  6. 17546

    Table 1_Identification of two KPC variants, KPC-204 and KPC-227, in ST11-K64 Klebsiella pneumoniae during prolonged hospitalization of a single patient.docx by Shijun Sun (9287651)

    Published 2025
    “…Introduction<p>Carbapenem-resistant Klebsiella pneumoniae (CRKP) represents a critical global public health challenge due to its significant association with morbidity and mortality. …”
  7. 17547
  8. 17548

    Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  9. 17549

    Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  10. 17550

    Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  11. 17551
  12. 17552

    Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  13. 17553
  14. 17554
  15. 17555

    Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  16. 17556

    Rht1 functions in cell cycle progression and modulates fluconazole susceptibility. by Ci Fu (148006)

    Published 2025
    “…Log rank (Mantel-Cox) test assessed significant difference between wild type and <i><i>rht1</i></i>Δ/Δ. …”
  17. 17557

    Attention reduces decision uncertainty under high cognitive demand. by Rahul Garg (3064578)

    Published 2025
    “…(L) Fraction of glomeruli with significant changes with cued-odor. Yellow: increased, dark grey: decreased, light grey: unchanged. …”
  18. 17558

    Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”
  19. 17559
  20. 17560

    Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

    Published 2025
    “…Liver stiffness by TE decreased in the SGLT2i group (−4.0 ± 1.1 kPa), while it increased in the insulin group (+3.0 ± 2.5 kPa; p < 0.01). …”